drugset / Trial / NCT02172105

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

NCT02172105

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to evaluate safety, tolerability, and pharmacokinetics of BI 1744 CL in healthy Japanese male volunteers.

Timeline

Start
2008-01
Primary completion
2008-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 5 ug Inhaled
Subject Olodaterol Small molecule 10 ug Inhaled
Subject Olodaterol Small molecule 20 ug Inhaled

Indications

No indication recorded.